Yakkan Shoumei (薬監証明) — the personal-import certificate and why it doesn't cover research peptides
Yakkan Shoumei (薬監証明), the medicines and medical devices import certificate, is the only PMD Act pathway for individuals to legally import unapproved pharmaceuticals into Japan. It is widely misunderstood in English-language research-peptide communities — operators routinely assume it covers research-use-only purchases, but the certificate is specifically structured around documented personal therapeutic use of substances approved elsewhere as therapeutic goods. This article documents the actual Yakkan Shoumei procedure (application form, required documents, quantity limits), explains why research peptides typically fail the eligibility test, and outlines the realistic alternatives.
Yakkan Shoumei is issued by the Yakuji Kanshi Shidouka (Pharmaceutical Affairs Inspection and Guidance Division) at one of the regional MHLW bureaus — Kanto-Shin'etsu (Tokyo), Kinki (Osaka), Tokai-Hokuriku, Kyushu, Chugoku-Shikoku, Tohoku, or Hokkaido. The applicant submits Form 37 (Yakkan Shoumei Koufu Shinseisho, 薬監証明交付申請書) to the regional bureau covering their port-of-entry, along with supporting documentation. The certificate is issued for a specific shipment, port, and quantity — it is not a blanket authorisation.
Required documents typically include: (1) a copy of the applicant's passport showing the name and signature page; (2) the prescription from a licensed physician for the substance, dated within a recent window; (3) the product information — including the active substance, dose form, quantity, and manufacturer; (4) shipping documentation showing consignor and consignee. For substances approved as pharmaceuticals in another stringent market (FDA, EMA, TGA, PMDA-equivalent), an English package insert or product labelling is accepted as evidence of therapeutic-good status. The application is in Japanese; English documents are accepted but a Japanese-language summary is often required.
Quantity limits are documented in MHLW guidance: a 2-month supply of an unapproved pharmaceutical for personal therapeutic use. Some categories (controlled drugs, hormones, certain injectables) have stricter limits or are categorically excluded. Insulin and human-use peptide hormones (somatropin, insulin analogs) — actual approved pharmaceuticals — have specific subcategory handling. Research peptides have no specific subcategory because they have no approved status.
The eligibility test that forecloses research peptides is the substance-must-be-approved-elsewhere requirement. Yakkan Shoumei is structurally for individuals importing medicines approved abroad for the importer's personal therapeutic use. BPC-157, TB-500, Selank, Semax, Epithalon — none are approved as therapeutic goods anywhere globally. They are research-use-only substances or unapproved investigational compounds. The certificate cannot be issued without a clear "approved as a therapeutic good in" answer for the substance.
An interesting edge case is Tirzepatide (Mounjaro / Zepbound, FDA-approved for diabetes and obesity). For a Japanese individual with a diabetes diagnosis and a prescription from a Japanese physician for Mounjaro, Yakkan Shoumei is procedurally available — Tirzepatide is approved in stringent markets and the personal-use exception applies. Research-grade Tirzepatide ordered from international peptide vendors does not qualify under Yakkan Shoumei because it is not the approved pharmaceutical product (different manufacturer, no GMP certification, no Japanese package insert). The distinction between approved pharmaceutical and research-grade is procedurally enforced.
GLP-1 analogs follow the same logic. Semaglutide (Ozempic / Wegovy / Rybelsus, FDA-approved) is procedurally importable under Yakkan Shoumei with a Japanese prescription, but research-grade semaglutide from international peptide vendors does not qualify. The PMD Act pathway is the approved-pharmaceutical version, not the research-use-only version, even if the chemical entity is identical. This is a critical distinction that operators often miss.
The realistic paths for individual researchers in Japan are: (1) Clinical Trial Notification (CTN) via an institutional sponsor — the documented compliant path for genuine research, requires affiliation with a university or research organisation; (2) order from UK-origin vendors with the best PMD Act customs track records (Pharma Lab Global, Direct Peptides) and accept non-zero interception; (3) for approved pharmaceuticals like Mounjaro / Ozempic / Wegovy, use a Japanese physician + Yakkan Shoumei for the approved product (not research-grade). PeptideGuide methodology weights "regional fulfilment" at 15% — JP customs experience is captured in the composite vendor score, and the JP vendor list pre-filters for vendors with adequate customs track record.
✓Pros
- Yakkan Shoumei is a documented PMD Act pathway with predictable procedural requirements
- For approved-pharmaceutical GLP-1s, Yakkan Shoumei + Japanese prescription is procedurally clean
- Regional MHLW bureaus handle applications in Japanese with documented response times
- Form 37 application process is published in MHLW guidance and English summaries exist
×Cons
- Yakkan Shoumei does not cover research-use-only substances — the substance-must-be-approved-elsewhere test forecloses BPC-157, TB-500, Selank, Semax, Epithalon
- Research-grade versions of approved pharmaceuticals (research-grade semaglutide, research-grade tirzepatide) do not qualify — only the approved manufacturer's version
- Application requires Japanese-language proficiency or translation support
- Quantity limited to 2-month supply; chronic-use protocols require repeat applications
- Edge cases (off-label use, atypical dosing) face individual reviewer discretion
What is Yakkan Shoumei in plain English?
Yakkan Shoumei (薬監証明) is a personal-import certificate issued by Japan's Ministry of Health, Labour and Welfare. It allows a Japanese individual to import an unapproved pharmaceutical for personal therapeutic use, with a 2-month quantity limit. The substance must be approved as a therapeutic good in another stringent regulatory market, and the applicant must have a prescription from a licensed physician.
Can I use Yakkan Shoumei to import BPC-157 or TB-500?
No. Yakkan Shoumei requires the substance to be approved as a therapeutic good somewhere. BPC-157, TB-500, Selank, Semax, Epithalon, GHK-Cu, and other research peptides are not approved as therapeutic goods anywhere globally — they are research-use-only or unapproved investigational compounds. The certificate cannot be issued.
What about Tirzepatide or Semaglutide — those are FDA-approved?
For an approved-pharmaceutical version (e.g., Eli Lilly's Mounjaro for Tirzepatide, Novo Nordisk's Ozempic / Wegovy for Semaglutide), Yakkan Shoumei is procedurally available with a Japanese physician's prescription. For research-grade versions ordered from international peptide vendors, the certificate is not issued — the same chemical entity in a research-use-only formulation from a non-GMP manufacturer is treated procedurally as a different product.
How long does the Yakkan Shoumei application take?
Regional MHLW bureaus typically process complete applications in 1–2 weeks. Incomplete applications (missing prescription, missing product info, missing Japanese summary) are returned with deficiency notices and reset the clock. The certificate is then valid for a specific shipment / port / quantity — it is not a blanket authorisation.
Which regional MHLW bureau handles my application?
The bureau covering your port of entry. Kanto-Shin'etsu (Tokyo) for Narita / Haneda. Kinki (Osaka) for Kansai International. Tokai-Hokuriku for Chubu Centrair / Komatsu. Kyushu for Fukuoka. Chugoku-Shikoku, Tohoku, Hokkaido for their respective regional airports / seaports. International couriers sometimes manage this via their customs broker; individual postal-import users handle directly.
What is the realistic path for Japanese researchers buying research peptides?
For institutional researchers: Clinical Trial Notification (CTN) under PMD Act Article 80-2, handled by the institution's procurement and customs broker. For non-institutional researchers: order from JP-shipping vendors with the best PMD Act customs track records (currently Pharma Lab Global and Direct Peptides, both UK-origin), accept that interception is non-zero, and avoid stealth packaging (misdeclaration is a more serious offence than honest research-chemical declaration). PeptideGuide does not endorse non-compliant import; we document the operational reality.
Is misdeclaration to make Yakkan Shoumei work a viable strategy?
No — and it is a serious offence under PMD Act + Customs Act. Declaring a research-use-only compound as an approved pharmaceutical to obtain Yakkan Shoumei is fraud against MHLW. Individual buyers caught misdeclaring face administrative penalties beyond simple seizure; bulk-import patterns can attract criminal investigation. Honest research-chemical declaration with accepted interception risk is the documented operational reality, not certificate fraud.
More from this region.
Other articles covering this region's vendors, regulatory framework, and research peptides.